MENLO PARK, Calif.--(BUSINESS WIRE)--Akoya Biosciences, Inc., today announced that data from its new line of multiplex immunofluorescence imaging platforms for high-parameter, spatially resolved ...
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
Did you enjoy our In Focus, sponsored by Bethyl Laboratories, on multiplex immunofluorescence for cancer research? Now you can access it all in one downloadable feature! Introducing In Focus Wrapped, ...
Historically, mRNA measurements have been tested on several commercially available platforms, but none have gained broad acceptance for assessment of HER2. An mRNA measurement, as a continuous value, ...
Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to identify biomarkers of ...
In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-PD1 and/or anti-PDL1 therapies, each single or in combination with ...
University of Zurich (UZH) scientists report that they have developed a new technique for analyzing cells and their components called Iterative Indirect Immunofluorescence Imaging (4i). They say this ...
As our attempts to develop more targeted and effective drugs continue, the need to better understand the protective and confounding effect of the tumor microenvironment grows. The study of such a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback